

### **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Maryanne Trevisan on 8-16-11.

The application has been amended as follows:

1) In claim 87, line 1, after 'a lipid suspension', 'for use with a perfluorocarbon gas as an ultrasound contrast agent' has been added.

On line 4, after 'non-aqueous solvent', 'wherein the phospholipids are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphotidic acid, mono sodium salt (DPPA) and N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, mono sodium salt (MPEG5000-DPPE)' has been added.

On line 5, after 'combining' the term, 'said' has been added.

On line 13, ',' has been deleted and '.' has been added.

Lines 14 to 19 have been deleted.

2) In claim 88, lines 1 and 4, 'lipids' has been changed to 'phospholipids'.

3) Claim 114 has been cancelled.

Art Unit: 1612

2. The following is an examiner's statement of reasons for allowance: The prior art on record does not teach or suggest the process of preparing the lipid suspension using the claimed combination of phospholipids for use with a perfluorocarbon gas as the ultrasound contrast agent.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore, PhD whose telephone number is (571)272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Krass Frederick can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1612

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gollamudi S. Kishore/  
Primary Examiner, Art Unit 1612

GSK